Cannabidiol displays unexpectedly high potency as an antagonist of CB₁and CB₂receptor agonists<i>in vitro</i>

Abstract

This study has provided the first evidence that cannabidiol can display CB2 receptor inverse agonism, an action that appears to be responsible for its antagonism of CP55940 at the human CB2 receptor. The ability of cannabidiol to behave as a CB2 receptor inverse agonist may contribute to its documented anti-inflammatory properties.